Member Info for Mithun

GOOD TO SEE IAN GO, ALL TALK NO ACTION, SP NOT AFFECTED GREATLY AS WE'RE ALREADY PRICED IN FOR FAILURE, HOPE THE NEW PERSON IN CHARGE IS SERIOUS TO MAKE THINGS HAPPEN, LETS GIVE HIM A CHANCE GLA

Hopefully we should break out before close today in readiness of next week's anticipated news. Gla

I agree sooner or later we should come together with other markets

Should give us a strong start gla

Looks like Zen has come alive again!!!

Successful Drilling Results

Zenith Energy Ltd., ("Zenith" or the "Company"), (LSE: ZEN; TSX.V: ZEE; OSE: ZENA-ME), the international oil & gas production company operating the largest onshore oilfield in Azerbaijan, is pleased to provide an update regarding drilling operations at well C-37 in the Jafarli oilfield.

The Company confirms that the deepening of well C-37 has successfully identified three untapped oil-bearing clastic layers in the Middle Eocene formation with a total net pay zone of approximately 16 metres.

Oil and gas shows recorded during drilling of these intervals have indicated the presence of favourable reservoir facies. Zenith is currently performing a series of wireline logs to enable a detailed evaluation of which intervals to perforate after the well is cased and cemented. Flow rates will be communicated once the well is placed on production.

The Company confirms that it has achieved its second objective of successfully drilling well C-37 to a total depth of 4,350 metres to test the Upper Cretaceous formation. This has evidenced a sequence of clay and carbonate facies which require further evaluation through wireline logs in order to ascertain the presence of possible oil-bearing reservoirs.

Preparatory work at well C-30

In line with Zenith's work programme, and further encouraged by the preliminary results achieved in the Middle Eocene formation of well C-37, the Company can confirm that civil works at well C-30 are expected to begin shortly.



Andrea Cattaneo, Chief Executive Officer of Zenith, commented:

"The first indications we have received from drilling operations at well C-37 are very encouraging. The approximately 16 metres of net pay zone we have identified confirm our confidence in the productivity of the Middle Eocene formation, historically a strong producer across our Azerbaijan asset, and the merits of deepening well C-37 in order to materially increase our daily production of oil.

I am also delighted with the performance of Zenith's service company subsidiary, Zena Drilling, during its first operational activities in Azerbaijan with our recently acquired 1,200hp drilling rig. We expect the speed of execution and efficiency of Zena to progressively optimise as we go forward in implementing our systematic drilling programme in Azerbaijan.

We look forward to completing operations at well C-37, and to communicating flow rates to the market as soon as they are determined."

Up 7% gla

Drilling to commence soon!

https://twitter.com/zenithenergyltd/status/1149211115127267328

Hopefully drilling activity this Monday coming gla!!!

I've been keeping an eye on the posts but not wrote anything recently but thought to share my opinion. Not many companies tweet with video evidence of the progress they make this is what I like about zenith. The rig is nearly ready for drilling activity and we still have people moaning. I agree it's not been a smooth ride but we are almost there and patience will truly be rewarded. This sp will be history once drilling commences and people will be jumping on the Zen wagon. Gla and hope we get the well deserved RNs by next week.

Above 0.50p good luck

thanks a lot looks like we have some major players in the game, lets hope we get some positive news soon gla!

Let's hope we can get back over 1p soon gla

Thanks Valju! much appreciated!

London UK., 26 March 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides the following update on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401. ValiRx is pleased to report that following ValiSeek's completion of its Phase II clinical trial and development (announced on 14 June 2018), ValiSeek has agreed Letters of Intent with one European and one US partner, about the further advancement of VAL401 into the next proposed clinical trial, on a co-financing basis. As an independent company, ValiSeek is seeking external financing towards the next trial, with all commercial negotiations continuing to be conducted by ValiSeek. Whilst ValiRx currently holds a 55.5 per cent. majority equity ownership of ValiSeek, the Company does not have any further financial and contractual requirements or commitments towards the remaining stages of ValiSeek's clinical development. ValiRx will benefit from all commercial returns, according to its shareholding, as per the ValiSeek Joint Venture agreement, announced on 8 April 2014. ValiRx is pleased to note the excellent progress of its investment and looks forward to sharing in ValiSeek's future commercial and therapeutic development. Dr Suzanne Dilly, CEO of ValiSeek, commented: "Progressing ValiSeek to the next phase of development is an exciting prospect, and with two partners already confirmed, I look forward to concluding arrangements to start the final clinical trials" Dr Satu Vainikka, CEO if ValiRx, commented: "I am delighted that ValiSeek has managed to secure a robust solution and strategy for the advancement of VAL401 and I believe that this outcome provides the best long-term value opportunity for ValiRx's investment in the ValiSeek project." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Thanks to the great valju! Who made the bod release this new in my opinion. I salute you!

Sorry matey just woke up lol good news at last!!!

London, UK., 26 March 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides the following update on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401. ValiRx is pleased to report that following ValiSeek's completion of its Phase II clinical trial and development (announced on 14 June 2018), ValiSeek has agreed Letters of Intent with one European and one US partner, about the further advancement of VAL401 into the next proposed clinical trial, on a co-financing basis. As an independent company, ValiSeek is seeking external financing towards the next trial, with all commercial negotiations continuing to be conducted by ValiSeek. Whilst ValiRx currently holds a 55.5 per cent. majority equity ownership of ValiSeek, the Company does not have any further financial and contractual requirements or commitments towards the remaining stages of ValiSeek's clinical development. ValiRx will benefit from all commercial returns, according to its shareholding, as per the ValiSeek Joint Venture agreement, announced on 8 April 2014. ValiRx is pleased to note the excellent progress of its investment and looks forward to sharing in ValiSeek's future commercial and therapeutic development. Dr Suzanne Dilly, CEO of ValiSeek, commented: "Progressing ValiSeek to the next phase of development is an exciting prospect, and with two partners already confirmed, I look forward to concluding arrangements to start the final clinical trials" Dr Satu Vainikka, CEO if ValiRx, commented: "I am delighted that ValiSeek has managed to secure a robust solution and strategy for the advancement of VAL401 and I believe that this outcome provides the best long-term value opportunity for ValiRx's investment in the ValiSeek project." This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

whos the new addition who mysteriously appeared and is telling everyone he knows it all, has he been banned previously?is he here for a reason? something is fishy

can someone post the link to the rns please, thanks